FDA Stings Beehive Botanicals For Web Links That "Fell Through The Cracks"
This article was originally published in The Rose Sheet
Executive Summary
Beehive Botanicals has endured product seizure, a complaint from FDA for making unapproved drug claims and potential damage to its reputation because it did not have a firm handle on all dimensions of its online business
You may also be interested in...
FDA Warns JabaLabs About Drug Claims For Anti-Aging Cosmetics
An FDA warning letter to San Antonio, Texas-based skin-care marketer JabaLabs, LLC signals that the agency is continuing its efforts to crack down on overreaching marketing claims for cosmetic products.
FDA Warns JabaLabs About Drug Claims For Anti-Aging Cosmetics
An FDA warning letter to San Antonio, Texas-based skin-care marketer JabaLabs, LLC signals that the agency is continuing its efforts to crack down on overreaching marketing claims for cosmetic products.
Beehive Botanicals consent decree approved
The U.S. District Court for the Western District of Wisconsin enters a consent decree of condemnation and injunction against Beehive Botanicals, under which the manufacturer agrees to forfeit certain bee-derived materials to the Department of Justice. The Hayward, Wis., company had product seized this year after FDA found its website made drug claims via links to other sites for its products, including creams and shampoos (1"The Rose Sheet" April 12, 2010). The decree, entered by the court May 14, additionally requires Beehive Botanicals to hire a third-party expert to inspect its labeling and certify the corrections to FDA, according to a DoJ release